Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
M Surowka, W Schaefer, C Klein - MAbs, 2021 - Taylor & Francis
Bispecific antibodies have recently attracted intense interest. CrossMab technology was
described in 2011 as novel approach enabling correct antibody light-chain association with …
described in 2011 as novel approach enabling correct antibody light-chain association with …
An engineered bispecific human monoclonal antibody against SARS-CoV-2
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
Engineering strategies of Anti-HIV antibody therapeutics in clinical development
N Pihlstrom, S Bournazos - Current Opinion in HIV and AIDS, 2023 - journals.lww.com
The development of Fc and Fab-engineered antibodies for the treatment of HIV continues to
show promising progress. These novel therapies have the potential to overcome the …
show promising progress. These novel therapies have the potential to overcome the …
Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
SARS-CoV-2 rapidly evolves during the pandemic 1 with many variants of concern (VoCs)
lineages (Supplementary Fig. S1a). Omicron (B. 1.1. 529) and its sub-lineages led to …
lineages (Supplementary Fig. S1a). Omicron (B. 1.1. 529) and its sub-lineages led to …
Design of a bispecific HIV entry inhibitor targeting the cell receptor CD4 and viral fusion protein Gp41
H Yan, T Wu, Y Chen, H Jin, L Li, Y Zhu… - Frontiers in Cellular …, 2022 - frontiersin.org
Given the high variability and drug-resistance problem by human immunodeficiency virus
type 1 (HIV-1), the development of bispecific or multi-specific inhibitors targeting different …
type 1 (HIV-1), the development of bispecific or multi-specific inhibitors targeting different …
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6
T Moshoette, MA Papathanasopoulos, MA Killick - Virology Journal, 2022 - Springer
The recently published AMP trial (HVTN 703/HPTN 081 and HVTN704/HPTN 085) results
have validated broad neutralising antibodies (bNAbs) as potential anti-HIV-1 agents …
have validated broad neutralising antibodies (bNAbs) as potential anti-HIV-1 agents …
Combinations of single chain variable fragments from HIV broadly neutralizing antibodies demonstrate high potency and breadth
Broadly neutralizing antibodies (bNAbs) are currently being assessed in clinical trials for
their ability to prevent HIV infection. Single chain variable fragments (scFv) of bNAbs have …
their ability to prevent HIV infection. Single chain variable fragments (scFv) of bNAbs have …
Engineering antibody-based molecules for HIV treatment and cure
M Tuyishime, G Ferrari - Current Opinion in HIV and AIDS, 2020 - journals.lww.com
Engineering antibody-based molecules for HIV treatment and c... : Current Opinion in HIV
and AIDS Engineering antibody-based molecules for HIV treatment and cure : Current …
and AIDS Engineering antibody-based molecules for HIV treatment and cure : Current …
Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1
S Li, Y Qiao, S Jiang, B Wang, W Kong… - Journal of Controlled …, 2021 - Elsevier
Broadly neutralizing antibodies (bNAbs) possess favorable safety, and passive
immunization using these can prevent or control human immunodeficiency virus type 1 (HIV …
immunization using these can prevent or control human immunodeficiency virus type 1 (HIV …
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
Monoclonal antibodies are a promising approach to treat COVID-19, however the
emergence of SARS-CoV-2 variants has challenged the efficacy and future of these …
emergence of SARS-CoV-2 variants has challenged the efficacy and future of these …